Second Phase 3 study results for LMTX published

November 29, 2017, IOS Press

TauRx Therapeutics Ltd today reported the full results from its second Phase 3 clinical study of LMTX, the first tau aggregation inhibitor in Alzheimer's disease, published online in the Journal of Alzheimer's Disease.

Results from this study (TRx-237-005) are consistent with those from the first Phase 3 study, recently published in The Lancet [(TRx-237-015) Gauthier et al. 20161] in mild to moderate Alzheimer's disease, in supporting the hypothesis that LMTX might be effective as at a dose as low as 4 mg twice daily.

The latest study (TRx-237-005) investigated the efficacy and safety of LMTX in 800 patients with mild Alzheimer's disease at a dose of either 100 mg or 4 mg (intended as the control dose) twice daily over an 18-month treatment period.

The results of the earlier study showed significant differences in favour of two higher doses of LMTX (75 mg and 125 mg twice daily) when taken as monotherapy compared with the intended 4 mg control dose taken as monotherapy or as add-on therapy to currently approved treatments for Alzheimer's disease in prespecified post hoc analyses. In a further analysis, the same difference in favour of monotherapy compared with add-on treatment was found in patients taking the 4 mg twice daily dose.

Therefore, prior to database lock and unblinding, the primary analyses of TRx-237-005 were modified to compare 100 mg LMTX twice daily as monotherapy with the intended control, and 4 mg twice daily as monotherapy compared with the same dose as add-on therapy as non-randomised cohort analyses. The aim was to test whether the findings from the first study could be confirmed as primary outcomes in a second independent study with strong controls against statistical error.

Results of the second study showed the same significant differences in favour of LMTX monotherapy at the required statistical threshold of p < 0.025 in both comparisons on the co-primary clinical efficacy endpoints for the cognitive (ADAS-cog) and functional (ADCS-ADL) outcomes.

In both the LMTX monotherapy and add-on therapy groups, whole brain atrophy (measured via MRI scans) initially progressed as expected for patients with mild Alzheimer's disease. However, after 9 months of treatment, the annualised rate of whole brain atrophy in monotherapy patients reduced significantly and became typical of that reported in normal elderly controls without Alzheimer's disease. The comparable rate seen in the add-on therapy group progressed as reported for patients with mild Alzheimer's disease.

Similarly, additional findings from FDG-PET scans in TRx-237-005 indicated that the decline in temporal lobe glucose uptake in those patients receiving LMTX monotherapy was significantly less than that typically reported for patients with mild Alzheimer's disease.

When the various analyses were corrected for potential differences in severity or diagnosis at baseline between monotherapy and add-on therapy cohorts, the results remained robustly significant.

"While the monotherapy subgroups in the first and second Phase 3 LMTX studies remain small – 15% and 20% respectively – the confirmation of the same pattern of results in the second independent study means they are unlikely to be a chance finding," said Prof. Claude Wischik, of Aberdeen University and executive chairman of TauRx Therapeutics Ltd.

"The overall retention rates in the second study were similar in both monotherapy and add-on treatment groups, so differential withdrawal rates cannot be the explanation. Likewise, seeing the same results in the second study conducted only in North America, Western Europe and Australia means that the first study was not atypical in some way through its inclusion of non-western countries. Finding the same pattern of results in the clinical and imaging outcomes also means that they cannot be explained as placebo effects in patients coming into a treatment setting for the first time."

Prof. Wischik went on to comment: "Although these results come from non-randomised cohort analyses, a number of things point to real effects and not just differences between patients taking or not taking the standard treatments. The analysis showing a slow-down in the brain atrophy rate is a before-and-after analysis in which the monotherapy patients were their own controls, and so does not depend on a comparison with add-on therapy patients. We are also starting to understand the pharmacologic basis of the negative interaction between LMTX and the standard treatments since we have now seen the same thing happening in an animal model of tau protein aggregation."

"These highly significant results support further validation of tau-based therapy in Alzheimer's disease," said George Perry, Dean of Sciences, University of Texas at San Antonio and Editor-in-Chief of the Journal of Alzheimer's Disease.

The lead author of the study, Gordon Wilcock, Emeritus Professor of Geratology and Honorary Clinical Senior Research Fellow in the Nuffield Department of Clinical Neurosciences at the University of Oxford, commented: "These data indicate the need for a further randomised controlled trial to evaluate efficacy of low dose LMTX in patients not taking current treatments."

Further randomised controlled studies of LMTX are set to commence shortly in which the 4 mg twice daily dose will be compared with placebo in with Alzheimer's who are not receiving other approved treatments for this condition (cholinesterase inhibitors and/or memantine).

Explore further: Promising drug trials for spin-out company in the fight against Alzheimer's disease

More information: Gordon K. Wilcock et al. Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial, Journal of Alzheimer's Disease (2017). DOI: 10.3233/JAD-170560

Related Stories

Promising drug trials for spin-out company in the fight against Alzheimer's disease

July 28, 2016
Phase three trials for a drug which targets Alzheimer's disease developed by a company spun out of the University of Aberdeen have shown promising results.

Lymphoma risk up with thiopurine, anti-TNF Tx in IBD

November 8, 2017
(HealthDay)—For patients with inflammatory bowel disease (IBD), the risk of lymphoma is increased with use of thiopurine monotherapy, anti-tumor necrosis factor (TNF) monotherapy, and combination therapy, according to a ...

Phase III tau drug fails to meet endpoints but shows silver lining as monotherapy

July 28, 2016
At AAIC2016, researchers from TauRx Therapeutics Ltd presented results from a phase III clinical trial of the drug leuco-methylthioninium-bis(hydromethanesulfonate) or LMTM in people with mild-to-moderate Alzheimer's disease.

VKA monotherapy linked to reduced MI, stroke risk in A-fib

June 20, 2017
(HealthDay)—For patients with atrial fibrillation (AF), vitamin K antagonist (VKA) monotherapy is associated with reduced risk of first-time myocardial infarction (MI) and stroke compared with acetylsalicylic acid (ASA) ...

Combo Tx superior for polypoidal choroidal vasculopathy

October 9, 2017
(HealthDay)—Combination therapy consisting of ranibizumab plus verteporfin photodynamic therapy (vPDT) is superior to ranibizumab monotherapy for treatment of eyes with polypoidal choroidal vasculopathy (PCV), according ...

Drug combo doesn't lengthen glioblastoma survival

November 17, 2017
(HealthDay)—In patients with progressive glioblastoma, treatment with lomustine plus bevacizumab does not confer a survival advantage over treatment with lomustine alone, according to a study published online Nov. 15 in ...

Recommended for you

DNA vaccine reduces both toxic proteins linked to Alzheimer's

November 20, 2018
A DNA vaccine tested in mice reduces accumulation of both types of toxic proteins associated with Alzheimer's disease, according to research that scientists say may pave the way to a clinical trial.

For Down syndrome adults, death and dementia often come together

November 19, 2018
(HealthDay)—Seven in 10 people with Down syndrome show evidence of dementia when they die, new research from Britain reveals.

Meditation and music may alter blood markers of cellular aging and Alzheimer's disease

November 13, 2018
A research team led by Dr. Kim Innes, a professor in the West Virginia University School of Public Health, has found that a simple meditation or music listening program may alter certain biomarkers of cellular aging and Alzheimer's ...

Alzheimer's and cardiovascular disease share common genetics in some patients

November 9, 2018
Genetics may predispose some people to both Alzheimer's disease and high levels of blood lipids such as cholesterol, a common feature of cardiovascular disease, according to a new study by an international team of researchers ...

Artificial intelligence predicts Alzheimer's years before diagnosis

November 6, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer's disease, according to a study published in the journal Radiology.

Diabetes medications may reduce Alzheimer's disease severity

November 1, 2018
People with Alzheimer's disease who were treated with diabetes drugs showed considerably fewer markers of the disease—including abnormal microvasculature and disregulated gene expressions—in their brains compared to Alzheimer's ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.